Équilibre Biopharmaceuticals
Mr. Bayat is Senior Vice President, Project Management at Equilibre Biopharmaceutical Corp. Prior to joining Equilibre, Mr. Bayat had leading roles in developing new drugs for treatment of hard-to-treat diseases, including planning and execution of development programs for Cyramza (ImClone / Eli Lilly), Sutent (Pfizer) and Rezurock (Kadmon), through regulatory filings, approvals and life-cycle-management, and development of INOpulse drug-device combination (Bellerophon). Mr. Bayat started his career as a Process Engineer and was responsible for the development, scale-up and commercial scale introduction of new chemical entities’ manufacturing processes as well as technology transfer to manufacturing sites in US, Europe and Mexico.
Mr. Bayat has a BS in Chemical Engineering from the University of Istanbul, a MS in Chemical Engineering from Louisiana Tech University, and an MBA from the University of Chicago Booth School of Business.
This person is not in any offices
Équilibre Biopharmaceuticals
Équilibre Biopharmaceuticals Corp. was established as an innovative biopharmaceutical company focused on identifying and developing high-potential drugs for patients who are treatment-resistant or unresponsive to other existing medications.